Efficacy of Secukinumab in Chinese Patients with Moderate-to-Severe Hidradenitis Suppurativa: A 16-Week, Single-Center, Prospective, Real-World Study.

Cosentyx (secukinumab) - Novartis

http://www.ncbi.nlm.nih.gov/pubmed/42741725

Chao Wu; Hong-Zhong Jin; Tie-Jun Liu; Xiao Ma; Xin-Yuan Zhang; Yong-Jun Wang

Sep 16, 2026